From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
MBL-IN-3 (compound 72922413) is a New Delhi metallo-β-lactamase-1 (NDM-1) inhibitor(IC50=54±4 μM). MBL-IN-3 is identified and shown to lower minimum inhibitory concentrations (MICs) of Meropenem (HY-13678) for a panel of E. coli and K. pneumoniae clinical isolates expressing NDM-1. MBL-IN-3 can be used for antibiotic sensitizer research .
MBL-IN-6 (Compound 6d) is a Metallo-β-lactamase (MBL) inhibitor with Kis of 2.6 and 0.08 μM for NDM-1 and VIM-2, respectively. MBL-IN-6 has a synergistic activities with Imipenem (HY-B1369A) on MBL-producing clinical isolates (such as E. coli SI-M001, K. pneumonia T2301 and S. marcescens SI-1591) with MICs of 2-64 μg/mL. MBL-IN-6 does not have off-target effects without ACE-1 inhibition activity. MBL-IN-6 can be used for antimicrobial resistance research .
Mbl2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Mbl2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
MBL2 Human Pre-designed siRNA Set A contains three designed siRNAs for MBL2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
MBL-IN-5 is a metallo-β-lactamase (MBL) inhibitor. MBL-IN-5 inhibits three clinically relevant B1 subfamily MBLs (NDM-1, VIM-1, and IMP-1) with IC50s of 0.05 nM, 14 nM and 21 nM respectively. MBL-IN-5 remarkably enhances carbapenems’ effectiveness against MBL-producing clinical strains and significantly reduces the bacterial load in a neutropenic murine thigh infection model combined with the IPM antibiotic .
MBL-IN-1 (compound 41) is a β-Lactamase inhibitor, with the IC50 ranging from 0.10 to 25.85 µM. MBL-IN-1 can be used for research of bacterial infections .
MBL-II-141 is potent ABCG2 inhibitor with an IC50 of 0.11 μM. MBL-II-141 inhibits the transport function of ABCG2 in a non-competitive manner, preventing ABCG2 from pumping substrates (such as Irinotecan (HY-16562)) out of the cells, thereby increasing the accumulation of drugs within the cells. MBL-II-141 has no effect on ABCB1 (P-gp) and ABCC1 (MRP1) and has extremely low cytotoxicity (IG50 > 100 μM). MBL-II-141 can be used for the study of multidrug resistance (MDR) cancers .
MBL-IN-2 ((2R, 2R')-5αC) is an inhibitor of Metallo-β-lactamase (MBL) that can inhibit New Delhi Metallo-β-lactamase-1 (NDM-1) with an IC50 of 0.3 μM. MBL-IN-2 ((2R, 2R')-5αC) can be used for the study of resistance to β-lactam antibiotics .
Mbl2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Mbl2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Bezlotoxumab (BLA761046; MBL-CDB1; MDX-1388) is a fully humanized IgG1/kappa monoclonal antibody directed against Clostridium difficile toxin B. Bezlotoxumab mediates the early reconstitution of gut microbiota to reduce the risk of recurrent Clostridium difficile infection (CDI). Bezlotoxumab can be used for the study of recurrent Clostridium difficile infection prevention .
FR295389 is a dihydroimidazopyrazolium cephalosporin with antibacterial activity. FR295389 shows activity against IMP-type metallo-β-lactamases (MBL)-producing Klebsiella pneumoniae, Acinetobacter baumanii and Pseudomonas putida with MIC values ranging from 4 to 32 mg/mL .
Metallo-β-lactamase-IN-15 (Compound ±13) is a potent MBL inhibitor, the IC50 values for NDM-1、IMP-1 and VIM-2 were 0.29 μM, 0.088 μM and 0.063 μM, respectively .
EBL-3183, an indole-2-carboxylate, is a potent metallo-β-lactamase (MBL) inhibitor. EBL-3183 is reversibly binding, non-covalent, competitive NDM-1 inhibitor with a pIC50 of 7.7 .
ANT2681 is a potent NDM inhibitor with a Ki value of 0.04 μM against NDM-1. ANT2681 also inhibits other MBLs, such as VIM-1 and IMP-1 with Ki values of 0.63 μM and 3.81 μM, respectively. ANT2681 can be used in combination with Meropenem (HY-13678) to inhibit infections caused by NDM-producing Enterobacteriaceae .
ZN148 is a zinc-chelating synthetic metallo-β-lactamase (MBL) inhibitor which attenuates MBL-mediated carbapenem resistance. ZN148 can restore the in vitro clinical susceptibility to carbapenems in >98% of a large international collection of MBL-producing clinical Enterobacterales strains. ZN148 can be utilized in research on anti MBL-producing bacteria .
Metallo-β-lactamase-IN-5 (compound 5c) is a potent metallo-β-lactamases (MBL) inhibitor. Metallo-β-lactamase-IN-5 shows inhibitory activity against MBLs NDM-1 and VIM-1. Metallo-β-lactamase-IN-5 inhibits HUVECs with an IC50 of 45 μg/mL. Metallo-β-lactamase-IN-5 plus Imipenem exhibits synergistic antimicrobial activity .
epi-D-Captopril (epi-D-SQ 14225) is a stereoisomer of Captopril (HY-B0368) and an inhibitor of metallo-β-lactamases (MBLs). The IC50 values of epi-D-Captopril against NDM-1, IMP-1, and VIM-2 are 64 μM, 173 μM, and 5.5 μM, respectively. epi-D-Captopril is expected to be used in the research of diseases caused by MBLs-related drug-resistant bacterial infections .
RPX 7546 is a potent inhibitor of metallo-𝛽-lactamases (MBLs) with IC50 values of 1.4 and 48 μM for IMP-1 and IMP-78, respectively. RPX 7546 has antibacterial activity .
YJ182 is a NDM-1 inhibitor (IC50: 0.23 μM). YJ182 also inhibits IMP-1, VIM-2, GIM-1, and MMP-2, with IC50s of 0.25, 0.61, 0.49, and 6.92 μM respectively. YJ182 can be used for bacterial infection research .
Metallo-β-lactamase-IN-9 (Compound 23) is a pan metallo-beta-lactamase (MBL) inhibitor with IC50s of 35, 269 and 369 nM against NDM-1, VIM-1 and IMP-1, respectively .
D-CS319 is a potent inhibitor of metallo-𝛽-lactamases (MBLs) with IC50 values of 2.0 and 3.0 μM for IMP-1 and IMP-78, respectively. D-CS319 has antibacterial activity .
Aspergillomarasmine A is a natural aminopolycarboxylic acid with potent inhibitory activity against class B metallo-β-lactamases (MBLs). Aspergillomarasmine A inactivates MBLs by removing a catalytic Zn2+ cofactor. Aspergillomarasmine A acts as a selective Zn2+ scavenger, promoting the dissociation of the metal cofactor, thereby indirectly inactivating NDM-1. Aspergillomarasmine A causes the loss of Zn2+ ions from the low-affinity binding site of NDM-1. The action of Aspergillomarasmine A results in the rapid degradation of Zn2+-deficient NDM-1, thereby enhancing its potency as a β-lactam enhancer. The mechanism of Aspergillomarasmine A has broad applicability among different Zn2+ chelators .
Metallo-β-lactamase-IN-4 (compound 40) is a potent metallo-β-lactamases (MBL) inhibitor, with IC50 values of 0.1 μM (VIM-1), 1.3 μM (NDM-1), and 5.0 μM (IMP-7), respectively .
Metallo-β-lactamase-IN-4 (compound 40) is a potent metallo-β-lactamases (MBL) inhibitor, with IC50 values of 0.5 μM (VIM-1), 2.1 μM (NDM-1), and 3.3 μM (IMP-7), respectively .
Metallo-β-lactamase-IN-3 (compound 35) is a potent metallo-β-lactamases (MBL) inhibitor. Metallo-β-lactamase-IN-3 shows high activity against VIM-1 and NDM-1, with IC50 of 0.6 and 1.0 μM, respectively. Metallo-β-lactamase-IN-3 does not show inhibition of IMP-7 .
Metallo-β-lactamase-IN-11 (compound 5f) is a Metallo-β-lactamases(MBLs) inhibitor, potent against bacterial metallophyllactamase CphA (IC50=45 µM). Metallo-β-lactamase-IN-11 (10 µM) inhibits NDM-1 by 49% and AIM-1 by 61%. Metallo-β-lactamase-IN-11 can be used in the research of inhibiting antibiotic resistance .
Metallo-β-lactamase-IN-6 is a potent VIM-Type metallo-β-lactamase inhibitor with IC50s of 0.56 μM, 29.50 μM and 5.78 μM for VIM-2, VIM-1 and VIM-5. Metallo-β-lactamase-IN-6 displays potent synergistic antibacterial activity with Meropenem against engineered Escherichia coli strains and intractable clinically isolated Pseudomonas aeruginosa producing VIM-2 MBL .
PIC1 PA, a 15 amino-acid peptide, is a potent PIC1 analog that inhibits classical pathway mediated complement activation. PIC1 PA functionally disrupts the C1s-C1r-C1r-C1s/MASPs interaction with collagen-like region (CLR) of C1q/MBL, respectively. PIC1 PA specifically binds to the CLR of C1q and bounds to purified C1q with a mean equilibrium dissociation constant (KD) of 33.3 nM .
PIC1 PA, a 15 amino-acid peptide, is a potent PIC1 analog that inhibits classical pathway mediated complement activation. PIC1 PA functionally disrupts the C1s-C1r-C1r-C1s/MASPs interaction with collagen-like region (CLR) of C1q/MBL, respectively. PIC1 PA specifically binds to the CLR of C1q and bounds to purified C1q with a mean equilibrium dissociation constant (KD) of 33.3 nM .
Bezlotoxumab (BLA761046; MBL-CDB1; MDX-1388) is a fully humanized IgG1/kappa monoclonal antibody directed against Clostridium difficile toxin B. Bezlotoxumab mediates the early reconstitution of gut microbiota to reduce the risk of recurrent Clostridium difficile infection (CDI). Bezlotoxumab can be used for the study of recurrent Clostridium difficile infection prevention .
Aspergillomarasmine A is a natural aminopolycarboxylic acid with potent inhibitory activity against class B metallo-β-lactamases (MBLs). Aspergillomarasmine A inactivates MBLs by removing a catalytic Zn2+ cofactor. Aspergillomarasmine A acts as a selective Zn2+ scavenger, promoting the dissociation of the metal cofactor, thereby indirectly inactivating NDM-1. Aspergillomarasmine A causes the loss of Zn2+ ions from the low-affinity binding site of NDM-1. The action of Aspergillomarasmine A results in the rapid degradation of Zn2+-deficient NDM-1, thereby enhancing its potency as a β-lactam enhancer. The mechanism of Aspergillomarasmine A has broad applicability among different Zn2+ chelators .
The MBL2/COLEC1 protein is a calcium-dependent lectin in innate immune defense that activates the lectin complement pathway by binding to mannose, fucose, and N-acetylglucosamine on microorganisms. MBL2/COLEC1 Protein, Human (HEK293, His) is the recombinant human-derived MBL2/COLEC1 protein, expressed by HEK293 , with C-6*His labeled tag.
C-type lectin domain-containing protein is a soluble mannose-binding protein in serum which belongs to the collectin family and is an important element in the innate immune system. C-type lectin domain-containing protein exerts mannose-binding, calcium-dependent protein binding and identical protein binding activity. MBL2/COLEC1 Protein, Mouse (HEK293) is the recombinant mouse-derived MBL2/COLEC1 protein, expressed by HEK293 , with tag free.
MBL1, a calcium-dependent lectin, recognizes microbial moieties, activating the lectin complement pathway.It also binds apoptotic and necrotic cells, aiding uptake by macrophages.As a homotrimer, MBL1 forms higher oligomeric complexes in the endoplasmic reticulum.MBL1's interaction with MASP1 and MASP2 enhances its role in immune response modulation and cellular recognition.MBL1 Protein, Mouse (HEK293, His) is the recombinant mouse-derived MBL1 protein, expressed by HEK293 , with N-His, N-6*His labeled tag.
MBL1 protein is a calcium-dependent lectin that participates in innate immunity by binding to mannose, fucose and N-acetylglucosamine on microorganisms and activating the lectin complement pathway.MBL1 Protein, Rat (HEK293, Fc) is the recombinant rat-derived MBL1 protein, expressed by HEK293 , with C-hFc labeled tag.
The CD93/C1qR1 protein is thought to be a receptor or part of a larger complex and plays a crucial role in immune recognition by binding to C1q, mannose-binding lectin (MBL2), and pulmonary surfactant protein A (SPA) .Its interaction with these immune factors suggests a role in coordinating the innate immune response.CD93/C1qR1 Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived CD93/C1qR1 protein, expressed by HEK293 , with C-Avi, C-His labeled tag.
Mbl2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Mbl2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
MBL2 Human Pre-designed siRNA Set A contains three designed siRNAs for MBL2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Mbl2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Mbl2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Inquiry Online
Your information is safe with us. * Required Fields.
